drugset / Trial / NCT05721287
A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults
RandomizedSequentialQuadruple-blindTreatment
Summary
This study will be a single-center, double-blind, randomized placebo-controlled, adaptive, single ascending dose study.
Timeline
- Start
- 2023-01-30
- Primary completion
- 2023-08-15
- Completion
- 2023-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SBS-1000 | Unknown | — | Intravenous |
Indications
No indication recorded.